TVCMALL bringer en one-stop grossistløsning til MWC 2023
Nylig ble Mobile World Congress (MWC) 2023 holdt i Barcelona, og det var en stor suksess. Mer enn 88 000 deltakere og 2400+ utstillere deltok i dette arrangementet, inkludert mange mobiltelefontilbehør leverandører og grossister. Som Europa sin ledende one-stop shop for mobiltilbehør og engros/integrert forsyningskjede-tjenesteplattform, TVCMALL deltok også i dette digitale/mobile arragementet. TVCMALL, basert i Shenzhen, Kina, som er verdens elektroniske senter, tilbyr kunder en B2B-løsning på mobiltilbehør for engros, innkjøp og spesialtilpasning. Forskjellige klassiske mobildeksler med lær-finish, ladere med multifunksjoner og Amorus bærbare karaoke-høyttalere fra TVCMALL fikk stor ros de som var til stede.
Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20230307005697/no/
TVCMALL brings one-stop wholesale solution to MWC 2023 (Photo: Business Wire)
MWC er en av verdens viktigste telekommunikasjons- og teknologimesser. I løpet av de siste 4 dagene har aspekter som den siste trenden innen mobilteknologi, inkludert intelligent utstyr, 5G-nettverk, AI og digitalisering, blitt introdusert og delt med resten av verden.
Under showet møtte TVCMALL mange gamle kunder og mange nye venner. Mange av dem er som følger:
- Topp forhandlere og distributører av mobiltelefontilbehør på nettet
- B2C-plattform selgere, Dropshippere
- Fysiske butikker, supermarked selgere, telekom selskaper
- Gave-Tilpassnings-kunder (spesielt for myndigheter, bedrifter, skoler og andre offentlige tjenester)
- OEM & ODM & OBM kunder
- Detaljhandel & Mobiltelefonverksteder
Mange kunder har samarbeidet med TVCMALL i over ti år siden etableringen i 2008, og de har vokst og utviklet seg raskt med TVCMALL. De uttrykte sin høye anerkjennelse og store takknemlighet til TVCMALL for å tilby en one-stop shop for engros, sourcing, spesialtilpassede tjenester og andre forsyningskjede tjenester.
Hvorfor velger de TVCMALL som en uunngåelig og viktig langsiktig samarbeidspartner? Fordi TVCMALL tilbyr en komplett produktkatalog, med mer enn 600 000 SKU på nettet, og hver uke oppdateres 6000 nye produkter. Grossistprosessen, markedsføringsstøtten og kundeservicen er effektive. TVCMALL har gode intensjoner om å vokse sammen med kundene sine.
TVCMALLs omfattende anskaffelseskostnad er relativt lav, tjenestekonsistensen og stabiliteten er meget sterk. Det er derfor mange kunder foretrekker one-stop tjenesteleverandører som TVCMALL.
Under MWC har TVCMALL etablert god kontak med noen utmerkede produktleverandører og e-handelstjenesteleverandører (av mobile, 3C elektroniske enheter og tilbehør).
I den nærmeste fremtiden, med kontinuerlig TVCMALL merkevare- og plattformoppgradering, vil TVCMALL styrke sitt mål, "Å hjelpe gründere med å aktualisere sine drømmer om å lansere og opprettholde en vellykket detaljhandel", og vil holde seg til sin forretningsdriftsfilosofi "Together we thrive". Når det gjelder spesifikke strategier, vil TVCMALL følge de 4 følgende retningene:
- Platform Branding — Operere TVCMALL-plattformen som en fremtidig århundre gammel merkevare
- Produktisering av tjenestene — alle tjenestene til TVCMALL sammen med ideen om produktisering.
- Produkt Dyp-pløying — For å være best må man trives.
- Lokalisering av TVCMALL-tjenesten — Gå globalt og lokalisere: Start lokalt markedsførings- og serviceteam, dybdeforståelse og effektiv service.
TVCMALL vil se deg igjen i Barcelona 2024!
Hvis du vil se dette innholdet fra cts.businesswire.com, gi ditt samtykke øverst på denne siden.
https://www.businesswire.com/news/home/20230307005697/no/
Contact information
Shenzhen Zhenzhi Technology Co.,Ltd.
Yelly Huang
global@tvcmall.com
https://www.tvcmall.com
Om Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg pressemeldinger fra Business Wire
Registrer deg med din e-postadresse under for å få de nyeste sakene fra Business Wire på e-post fortløpende. Du kan melde deg av når som helst.
Siste pressemeldinger fra Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin